Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
J Integr Neurosci ; 23(1): 24, 2024 Jan 22.
Article in English | MEDLINE | ID: mdl-38287860

ABSTRACT

OBJECTIVE: Absence seizures result from aberrant thalamocortical processing that confers synchronous, bilateral spike-and-wave discharges (SWDs) and behavioral arrest. Previous work has demonstrated that SWDs can result from enhanced thalamic tonic inhibition, consistent with the mechanism of first-line antiabsence drugs that target thalamic low-voltage-activated calcium channels. However, nearly half of patients with absence epilepsy are unresponsive to first-line medications. In this study we evaluated the role of cortical tonic inhibition and its manipulation on absence seizure expression. METHODS: We used video-electroencephalogram (EEG) monitoring to show that mice with a γ-aminobutyric acid type A (GABAA) receptor mutation (γ2R43Q) display absence seizures. Voltage-clamp recordings in brain slices from wild type and γ2R43Q mice were used to evaluate the amount of tonic inhibition and its selective pharmacological modulation. Finally, we determined whether modulating tonic inhibition controls seizure expression. RESULTS: γ2R43Q mice completely lack tonic inhibition in principal neurons of both layer 2/3 cortex and ventrobasal thalamus. Blocking cortical tonic inhibition in wild type mice is sufficient to elicit SWDs. Tonic inhibition in slices from γ2R43Q mice could be rescued in a dose-dependent fashion by the synthetic neurosteroid ganaxolone. Low-dose ganaxolone suppressed seizures in γ2R43Q mice. CONCLUSIONS: Our data suggest that reduced cortical tonic inhibition promotes absence seizures and that normal function can be restored via selective pharmacological rescue. These results, together with previous findings, suggest that deviations of tonic inhibition either above or below an optimal set point can contribute to absence epilepsy. Returning the thalamocortical system to this set point may provide a novel treatment for refractory absence epilepsy.


Subject(s)
Epilepsy, Absence , Humans , Mice , Animals , Epilepsy, Absence/drug therapy , Epilepsy, Absence/genetics , Seizures , Brain , Thalamus , Electroencephalography
2.
NPJ Parkinsons Dis ; 8(1): 103, 2022 Aug 10.
Article in English | MEDLINE | ID: mdl-35948563

ABSTRACT

Several mutations that cause Parkinson's disease (PD) have been identified over the past decade. These account for 15-25% of PD cases; the rest of the cases are considered sporadic. Currently, it is accepted that PD is not a single monolithic disease but rather a constellation of diseases with some common phenotypes. While rodent models exist for some of the PD-causing mutations, research on the sporadic forms of PD is lagging due to a lack of cellular models. In our study, we differentiated PD patient-derived dopaminergic (DA) neurons from the induced pluripotent stem cells (iPSCs) of several PD-causing mutations as well as from sporadic PD patients. Strikingly, we observed a common neurophysiological phenotype: neurons derived from PD patients had a severe reduction in the rate of synaptic currents compared to those derived from healthy controls. While the relationship between mutations in genes such as the SNCA and LRRK2 and a reduction in synaptic transmission has been investigated before, here we show evidence that the pathogenesis of the synapses in neurons is a general phenotype in PD. Analysis of RNA sequencing results displayed changes in gene expression in different synaptic mechanisms as well as other affected pathways such as extracellular matrix-related pathways. Some of these dysregulated pathways are common to all PD patients (monogenic or idiopathic). Our data, therefore, show changes that are central and convergent to PD and suggest a strong involvement of the tetra-partite synapse in PD pathophysiology.

3.
J Neurosci ; 39(37): 7438-7449, 2019 09 11.
Article in English | MEDLINE | ID: mdl-31350261

ABSTRACT

Mutations in the KCNT1 (Slack, KNa1.1) sodium-activated potassium channel produce severe epileptic encephalopathies. Expression in heterologous systems has shown that the disease-causing mutations give rise to channels that have increased current amplitude. It is not known, however, whether such gain of function occurs in human neurons, nor whether such increased KNa current is expected to suppress or increase the excitability of cortical neurons. Using genetically engineered human induced pluripotent stem cell (iPSC)-derived neurons, we have now found that sodium-dependent potassium currents are increased several-fold in neurons bearing a homozygous P924L mutation. In current-clamp recordings, the increased KNa current in neurons with the P924L mutation acts to shorten the duration of action potentials and to increase the amplitude of the afterhyperpolarization that follows each action potential. Strikingly, the number of action potentials that were evoked by depolarizing currents as well as maximal firing rates were increased in neurons expressing the mutant channel. In networks of spontaneously active neurons, the mean firing rate, the occurrence of rapid bursts of action potentials, and the intensity of firing during the burst were all increased in neurons with the P924L Slack mutation. The feasibility of an increased KNa current to increase firing rates independent of any compensatory changes was validated by numerical simulations. Our findings indicate that gain-of-function in Slack KNa channels causes hyperexcitability in both isolated neurons and in neural networks and occurs by a cell-autonomous mechanism that does not require network interactions.SIGNIFICANCE STATEMENTKCNT1 mutations lead to severe epileptic encephalopathies for which there are no effective treatments. This study is the first demonstration that a KCNT1 mutation increases the Slack current in neurons. It also provides the first explanation for how this increased potassium current induces hyperexcitability, which could be the underlining factor causing seizures.


Subject(s)
Epilepsy/genetics , Induced Pluripotent Stem Cells/physiology , Mutation/physiology , Nerve Tissue Proteins/genetics , Neurons/physiology , Potassium Channels, Sodium-Activated/genetics , Action Potentials/physiology , Cell Differentiation/physiology , Epilepsy/physiopathology , HEK293 Cells , Humans
4.
Stem Cell Reports ; 9(1): 149-161, 2017 07 11.
Article in English | MEDLINE | ID: mdl-28579395

ABSTRACT

A major challenge for clinical application of pluripotent stem cell therapy for Parkinson's disease (PD) is large-scale manufacturing and cryopreservation of neurons that can be efficiently prepared with minimal manipulation. To address this obstacle, midbrain dopamine neurons were derived from human induced pluripotent stem cells (iPSC-mDA) and cryopreserved in large production lots for biochemical and transplantation studies. Cryopreserved, post-mitotic iPSC-mDA neurons retained high viability with gene, protein, and electrophysiological signatures consistent with midbrain floor-plate lineage. To test therapeutic efficacy, cryopreserved iPSC-mDA neurons were transplanted without subculturing into the 6-OHDA-lesioned rat and MPTP-lesioned non-human-primate models of PD. Grafted neurons retained midbrain lineage with extensive fiber innervation in both rodents and monkeys. Behavioral assessment in 6-OHDA-lesioned rats demonstrated significant reversal in functional deficits up to 6 months post transplantation with reinnervation of the host striatum and no aberrant growth, supporting the translational development of pluripotent cell-based therapies in PD.


Subject(s)
Cryopreservation , Dopaminergic Neurons/cytology , Dopaminergic Neurons/transplantation , Induced Pluripotent Stem Cells/cytology , Parkinson Disease/therapy , Animals , Cell Line , Corpus Striatum/cytology , Corpus Striatum/pathology , Cryopreservation/methods , Disease Models, Animal , Dopamine/metabolism , Dopaminergic Neurons/metabolism , Haplorhini , Humans , Mesencephalon/cytology , Mesencephalon/pathology , Neurogenesis , Parkinson Disease/pathology , Rats , Rats, Sprague-Dawley
5.
Cell ; 129(5): 851-3, 2007 Jun 01.
Article in English | MEDLINE | ID: mdl-17540162

ABSTRACT

Does neuronal loss associated with dementia necessarily impair the ability to learn new information and recall old memories? In a recent report in Nature, Fischer et al. (2007) show that the ability to learn and remember can be reestablished in a mouse model of dementia through either environmental enrichment or chronic treatment with an inhibitor of histone deacetylase.


Subject(s)
Dementia/therapy , Nerve Degeneration/therapy , Animals , Dementia/drug therapy , Disease Models, Animal , Enzyme Inhibitors/therapeutic use , Histone Deacetylase Inhibitors , Learning , Memory , Mice , Nerve Degeneration/drug therapy
6.
PLoS One ; 1: e138, 2006 Dec 27.
Article in English | MEDLINE | ID: mdl-17205142

ABSTRACT

The formation of enduring internal representation of sensory information demands, in many cases, convergence in time and space of two different stimuli. The first conveys the sensory input, mediated via fast neurotransmission. The second conveys the meaning of the input, hypothesized to be mediated via slow neurotransmission. We tested the biochemical conditions and feasibility for fast (NMDA) and slow (dopamine) neurotransmission to converge on the Mitogen Activated Protein Kinase signaling pathways, crucial in several forms of synaptic plasticity, and recorded its effects upon synaptic transmission. We detected differing kinetics of ERK2 activation and synaptic strength changes in the CA1 for low and high doses of neurotransmitters in hippocampal slices. Moreover, when weak fast and slow inputs are given together, they converge on ERK2, but not on p38 or JNK, and induce strong short-term synaptic depression. Surprisingly, pharmacological analysis revealed that a probable site of such convergence is the NMDA receptor itself, suggesting it serves as a detector and integrator of fast and slow neurotransmission in the mature mammalian brain, as revealed by ERK2 activation and synaptic function.


Subject(s)
Dopamine/metabolism , Hippocampus/metabolism , Long-Term Synaptic Depression/physiology , MAP Kinase Signaling System , N-Methylaspartate/metabolism , Receptors, N-Methyl-D-Aspartate/metabolism , Animals , CA1 Region, Hippocampal/drug effects , CA1 Region, Hippocampal/metabolism , Dopamine/administration & dosage , Enzyme Activation/drug effects , Hippocampus/drug effects , In Vitro Techniques , Kinetics , Long-Term Synaptic Depression/drug effects , MAP Kinase Signaling System/drug effects , Male , Mitogen-Activated Protein Kinase 1/metabolism , Models, Neurological , N-Methylaspartate/administration & dosage , Rats , Rats, Sprague-Dawley , Receptors, AMPA/metabolism , Synaptosomes/drug effects , Synaptosomes/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...